Clinical trial

Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis

NCT07587125

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-05-08

PhasePHASE1

Study timeline

Study start (actual)2026-05-08Date precision: day

Registry last updated2026-08-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis (MS) Primary Progressiveunresolved

Multiple Sclerosisunresolved

Multiple Sclerosis (MS) Secondary Progressiveunresolved

Refractory Multiple Sclerosisunresolved

Interventions

Sponsors & collaborators

Xijing Hospitallead sponsor

Hebei Senlang Biotechnology Co., LTDcollaborator

Mapped research locations

Xi'anShaanxi, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07587125 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.